Pharmaceutical Care in Emergency Department (AMPaRAR)

Hospital Moinhos de Vento

Status: Completed

Conditions: Hypertension; Medication Adherence; Diabetes Mellitus

Treatments: Other: Pharmaceutical care

Study type: Interventional

Funder types: Other

Identifiers

NCT01978925

AMPaRAR 01

Details and patient eligibility

About

The purpose of this study is to evaluate the effectiveness of pharmaceutical care, compared to usual care, in patient discharge in an emergency department in patients with hypertension and/or diabetes mellitus type 2.

Full description

This is a randomized controlled, single-center study, with blinding of outcome assessors. A pilot study with ten patients was previously conducted in order to test study logistics and data collection instruments. Participants will be recruited from a public ED at Restinga district in Porto Alegre, southern Brazil.

Enrollment: 380 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Blood pressure inadequate control (systolic blood pressure ≥ 160 or diastolic blood pressure ≥ 100 mmHg) or
• Diabetes mellitus inadequate Control( ≥ 200 mg/dL) or hypoglycemia moderate or severe
• Be referred to clinical care.

Exclusion criteria

• < 18 years
• Not resident of Porto Alegre
• Diabetes mellitus type I
• Unable to answer the questionnaire or to sign the informed consent form
• Hospital admission
• Death

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

380 participants in 2 patient groups

Pharmaceutical care

Experimental group

Description:

In the ED, immediately after discharge, participants randomized to the pharmaceutical care group will receive intervention coordinated by the study pharmacist.

Treatment:

Other: Pharmaceutical care

Usual care

No Intervention group

Description:

In addition to counseling provided by a physician and by the nursing staff during their stay in the ED (usual care), patients randomized to the control group will receive the same printed material information on hypertension and/or diabetes medications and lifestyle interventions in order to keep patients masked.